Daily Cosmetic Research Analysis
Safety and materials innovation dominate today’s cosmetic-related research. Human embryonic stem cell models indicate synthetic phenolic antioxidants and BHT transformation products may disrupt early embryonic and skin differentiation and act as skin sensitizers. Concurrently, a triple-modified PEEK dental surface shows enhanced soft-tissue compatibility and antibacterial performance, while an updated RIFM safety assessment supports controlled use of a fragrance ingredient under TTC-based exposu
Summary
Safety and materials innovation dominate today’s cosmetic-related research. Human embryonic stem cell models indicate synthetic phenolic antioxidants and BHT transformation products may disrupt early embryonic and skin differentiation and act as skin sensitizers. Concurrently, a triple-modified PEEK dental surface shows enhanced soft-tissue compatibility and antibacterial performance, while an updated RIFM safety assessment supports controlled use of a fragrance ingredient under TTC-based exposure limits.
Research Themes
- Cosmetics safety/toxicology (developmental and skin sensitization risks)
- Dental biomaterials for aesthetic and infection control outcomes
- Regulatory risk assessment and exposure-based safety thresholds
Selected Articles
1. Developmental toxicity and skin sensitization potential of synthetic phenolic antioxidants and butylated hydroxytoluene transformation products: Insights from human embryonic stem cell models.
Using human embryonic stem cell differentiation systems, the authors show that synthetic phenolic antioxidants and BHT transformation products perturb early germ layer specification and disrupt keratinocyte maturation. The transcriptional signatures include psoriasis-associated and pro-inflammatory genes, indicating potential skin sensitization and developmental risks.
Impact: This study provides mechanistic human-relevant evidence for cosmetic antioxidant safety concerns, bridging developmental biology and dermatotoxicology. It informs risk assessment for pregnancy and adult skin exposure.
Clinical Implications: Clinicians and regulators should consider limiting SPA exposures in pregnant individuals and those with inflammatory dermatoses, and encourage substitution with safer alternatives pending in vivo validation. Counseling on product selection during pregnancy may reduce potential risks.
Key Findings
- SPAs and BHT-TPs up-regulated neural ectoderm/neural crest genes and down-regulated surface ectoderm/primitive streak genes during hESC differentiation.
- In a skin-specific differentiation model, these compounds inhibited maturation of keratinocyte progenitors into mature keratinocytes.
- Gene programs associated with psoriasis, pro-inflammatory cytokines, and chemokines were up-regulated, suggesting potential skin sensitization.
Methodological Strengths
- Use of human embryonic stem cell monolayer and skin-specific differentiation models increases human relevance.
- Comprehensive transcriptional readouts across germ layer and keratinocyte lineage markers.
- Parallel assessment of multiple compound classes (SPAs and BHT transformation products).
Limitations
- In vitro models without in vivo or human exposure confirmation.
- Concentration ranges and real-world exposure equivalence are not detailed.
- Mixture effects and long-term outcomes were not assessed.
Future Directions: Validate findings in animal models and human observational cohorts, establish exposure-response relationships, identify safer alternatives, and evaluate mixture effects relevant to cosmetic formulations.
Synthetic phenolic antioxidants (SPAs) are commonly used in food, cosmetics, and other products for their antioxidant properties and stability. However, increasing evidence links excessive SPA use to adverse effects, including developmental issues in animals. Given the widespread use of SPAs in cosmetics, there is a growing need to assess their potential health risks, particularly whether safe to be used during pregnancy. This study investigates the early developmental toxicity of SPAs using a human embryonic stem cell (hESC) monolayer differentiation model. Results show that SPAs and butylated hydroxytoluene transformation products (BHT-TPs) up-regulated neural ectoderm and neural crest genes while down-regulated surface ectoderm and primitive streak genes during differentiation. Furthermore, in a skin-specific differentiation model, SPAs and BHT-TPs disrupted keratinocyte differentiation, inhibiting the differentiation of keratinocyte progenitors into more mature keratinocytes. They also led to the up-regulation of genes associated with psoriasis, pro-inflammatory cytokines, and chemokines, suggesting the potential of SPAs to act as skin sensitizers. These findings suggest that SPAs may affect early embryonic development at an early germ layer specification stage, as well as during skin development, potentially increasing skin sensitivity. Thus, excessive SPA use in cosmetics could pose risks to fetal development and adult skin health.
2. Triple-modified PEEK surface via plasma treatment, polydopamine coating and chlorhexidine: Assessment of biocompatibility and antibacterial properties.
A triple-modification of PEEK (plasma, polydopamine, and chlorhexidine) yields a hydrophilic, nano-rough surface that supports gingival fibroblast adhesion/proliferation and provides sustained CHX release with reduced bacterial adhesion and biofilm. These dual biological and antibacterial benefits position PEEK as a promising aesthetic dental abutment material.
Impact: Simultaneous enhancement of soft-tissue integration and antibacterial function addresses two key failure modes of dental implants (soft-tissue seal and peri-implant infection).
Clinical Implications: If validated in vivo, such surfaces could reduce peri-implant mucositis/implantitis while maintaining aesthetics in PEEK abutments and customized prosthetics; sustained CHX release may decrease early colonization and biofilm formation.
Key Findings
- Contact angle decreased from 83.6° to 24.2° and surface roughness increased (0.38 μm vs 0.28–0.33 μm), indicating improved hydrophilicity and topography.
- Human gingival fibroblasts showed enhanced adhesion, proliferation, spreading, and cytoskeletal organization on modified PEEK.
- P-PDA-CHX provided sustained chlorhexidine release over 15 days and significantly reduced bacterial adhesion and biofilm formation.
Methodological Strengths
- Comprehensive physicochemical characterization (SEM, FTIR, XPS, profilometry, contact angle).
- Biological validation with primary human cells and multi-assay antibacterial testing.
- Direct comparison among plasma-only, PDA-only, CHX-only, and combined modifications.
Limitations
- In vitro only; no animal or clinical validation.
- Limited release period (15 days) and uncertain performance under oral conditions (saliva, load, aging).
Future Directions: Evaluate long-term mechanical durability, oral environment aging, microbiome interactions, and in vivo performance; compare against titanium and zirconia abutments in randomized clinical studies.
OBJECTIVE: To develop and evaluate a novel surface modification strategy for polyetheretherketone (PEEK) that combines cold plasma treatment with dopamine-crosslinked chlorhexidine (CHX) to enhance both soft tissue integration and antimicrobial properties for potential dental applications. METHODS: PEEK surfaces were modified through cold plasma treatment followed by polydopamine (PDA) coating and CHX functionalization. Surface characterization was performed by SEM, FTIR, XPS, profilometer and contact angle measurements. A 15-day CHX in vitro release test was conducted to evaluate the drug delivery profile of the modified surfaces. Biological response was evaluated through human gingival fibroblasts (HGFs) cultures, examining cell adhesion and proliferation capacity. Antimicrobial efficacy was systematically evaluated through bacterial viability, colony enumeration, biofilm formation, and adhesion analysis. RESULTS: The P-PDA-CHX modification significantly improved surface hydrophilicity, reducing contact angles from 83.6 ± 3.1° to 24.2 ± 4.2°. Surface roughness of P-PDA-CHX (0.38 ± 0.029 μm) was significantly higher than that of the P-PDA (0.28 ± 0.048 μm) and P-CHX (0.33 ± 0.033 μm) groups (p < 0.05). Compared to unmodified surfaces, the modified surfaces demonstrated enhanced HGFs proliferation and adhesion, with cells showing improved spreading and cytoskeletal organization. The P-PDA-CHX coating exhibited sustained chlorhexidine release over 15 days and demonstrated superior antibacterial properties, significantly reducing bacterial adhesion and biofilm formation while maintaining excellent biocompatibility with HGFs. SIGNIFICANCE: This surface modification strategy offers a promising approach for improving PEEK's biological and antibacterial properties. The combination of cold plasma treatment, PDA coating, and CHX functionalization provides a solution to enhance both cellular response and bacterial resistance, which could benefit various dental applications of PEEK materials, including customized abutments, where tissue integration and bacterial control are essential.
3. Update to RIFM fragrance ingredient safety assessment, 4,4a,6,7,8,8a-hexahydro-1,4-methanonaphthalen-5(1H)-one, CAS Registry Number 51519-65-4.
RIFM’s updated assessment concludes the fragrance ingredient is non-genotoxic and that consumer exposures are below TTC thresholds for repeated dose, reproductive, and local respiratory toxicity for a Cramer Class III substance. Read-across supports a NESIL of 5300 μg/cm…, informing safe-use levels for skin sensitization management.
Impact: Provides a transparent, endpoint-by-endpoint safety synthesis using TTC and read-across approaches central to cosmetic risk assessment, directly informing formulation limits and consumer safety.
Clinical Implications: Dermatology and occupational health stakeholders can use the NESIL and TTC-based exposure limits to minimize skin sensitization risk and inform labeling and safe-use concentrations.
Key Findings
- The ingredient is non-genotoxic based on available data.
- Exposures are below TTC thresholds for repeated dose and reproductive toxicity (0.0015 mg/kg/day) and local respiratory toxicity (0.47 mg/day).
- Read-across from an analog supports a No Expected Sensitization Induction Level (NESIL) of 5300 μg/cm…
Methodological Strengths
- Endpoint-spanning assessment including genotoxicity, systemic, respiratory, photoirritation/photoallergenicity, sensitization, and environmental safety.
- Use of TTC for Cramer Class III and read-across to derive sensitization benchmarks.
Limitations
- Relies on TTC and read-across rather than new human clinical data.
- Abstract does not detail photoirritation/photoallergenicity outcomes or full NESIL units.
Future Directions: Confirm sensitization thresholds with human repeat insult patch tests, refine consumer exposure modeling, and assess susceptible subpopulations.
4,4a,6,7,8,8a-Hexahydro-1,4-methanonaphthalen-5(1H)-one was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety. Data show that 4,4a,6,7,8,8a-hexahydro-1,4-methanonaphthalen-5(1H)-one is not genotoxic. The repeated dose, reproductive, and local respiratory toxicity endpoints were evaluated using the Threshold of Toxicological Concern (TTC) for a Cramer Class III material, and the exposure to 4,4a,6,7,8,8a-hexahydro-1,4-methanonaphthalen-5(1H)-one is below the TTC (0.0015 mg/kg/day, 0.0015 mg/kg/day, and 0.47 mg/day, respectively). Data from read-across analog octahydro-7-methyl-1,4-methanonaphtalen-6(2H)-one (CAS # 41724-19-0) provide 4,4a,6,7,8,8a-hexahydro-1,4-methanonaphthalen-5(1H)-one a No Expected Sensitization Induction Level (NESIL) of 5300 μg/cm